Forschungsprojekte
Ergebnisse pro Seite:
10
2022 - 2026
Exploring KrasG12V-specific TCR-like CAR redirected T cells for immunotherapy in non-small cell lung cancer (NSCLC)- PD Dr. Udo Hartwig
2022 - 2026
Targeting chromatin complexes to reverse AML immune escape for engineered cell therapy (SFB 1292/2, TP 12)- Dr. Michael Kühn,
- Prof. Dr. Evelyn Ullrich
2022 - 2040
International phase III, open label, multi-centre, randomised, collaborative treatment optimizing Trial (#1419)- Dr. Marius Fried
2022 - 2025
Lebensqualität von Patienten und deren Bettpartnern vor und nach Implantation eines Hypoglossus-Neurostimulators (HGNS)- Prof. Dr. Haralampos Gouveris
2022 - 2040
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (#1418)- Prof. Dr. Markus Radsak
2022 - 2026
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle InvasiveBladder Cancer (VOLGA)- PD Dr. med. Maximilian Brandt,
- PD Dr. Rene Mager,
- Dr. Anita Thomas
2022 - 2025
Kompatibilität und Stabilität von applikationsfertigen Parenteralia- Prof. Dr. Irene Krämer,
- Zoe Mittmann,
- Dr. Judith Thiesen
2022 - 2027
Analysis of antibody responses against tumor-derived neo-antigens in triple-negative breast cancer (TNBC)- Univ.-Prof. Dr. Marcus Schmidt,
- PD Dr. Anne-Sophie Heimes
2022 - 2027
Characterization of the immunoglobulin repertoire of tumor-infiltrating plasma cells and correlation of factors within the plasma with prognosis in early breast cancer- Univ.-Prof. Dr. Marcus Schmidt,
- PD Dr. Anne-Sophie Heimes